BioCentury | May 30, 2020
Management Tracks

Schneyer named Acadia CBO; plus Hansa, MaaT, iOnctura, First Light, Oligomerix, Galecto and Hyloris

...Kaufhold will become CMO, a newly created position. Before joining the autoimmune company, he served Basilea Pharmaceutica Ltd....
BioCentury | Jan 24, 2020
Preclinical News

Jan. 23 Preclinical Quick Takes: Metastasis-associated cancer-associated fibroblast populations; plus NIH-TeneoBio and Basilea

...a presentation at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO), Basilea Pharmaceutica Ltd....
...growth factor β BioCentury Staff TeneoBio Inc. Institut Curie Institut National de la Sante et de la Recherche Medicale (INSERM) Basilea Pharmaceutica Ltd. National...
BioCentury | May 2, 2019
Company News

Forge, Basilea to develop antibiotics against unexploited targets

...plus tiered royalties. Basilea Pharmaceutica International Ltd. is a subsidiary of Basilea Pharmaceutica Ltd. (SIX:BSLN). Shannon Lehnbeuter, Staff Writer Basilea Pharmaceutica Ltd. Forge...
BioCentury | Feb 12, 2019
Company News

Management tracks: Sanofi, Alexion, bluebird

...succeeds Eva-Maria Joed, who will become VP of finance and administration. Spota was CFO at Basilea Pharmaceutica AG...
BioCentury | Jan 18, 2019
Clinical News

Derazantinib leads to 21% ORR in Phase II intrahepatic cholangiocarcinoma cohort

...also plans to start in mid-2019 a Phase II trial in other FGFR-driven solid tumors. Basilea Pharmaceutica Ltd....
...ORR); disease control rate (DCR) Status: Interim Phase II data Milestone: NA Hongjiang Li Derazantinib (ARQ 087) ArQule Inc. Basilea Pharmaceutica Ltd. Fibroblast...
BioCentury | Apr 20, 2018
Company News

Basilea gains rights to ArQule's derazantinib

...ArQule Inc. (NASDAQ:ARQL) granted Basilea Pharmaceutica Ltd. (SIX:BSLN) exclusive rights to develop and commercialize derazantinib (ARQ 087) outside...
...derazantinib. ArQule Inc. (NASDAQ:ARQL), Burlington, Mass. Basilea Pharmaceutica Ltd. (SIX:BSLN), Basel, Switzerland Business: Cancer Jennie Walters Derazantinib (ARQ 087) ArQule Inc. Basilea Pharmaceutica Ltd. The...
BioCentury | Apr 17, 2018
Company News

Basilea gains rights to ArQule's derazantinib

...ArQule Inc. (NASDAQ:ARQL) shares rose $0.46 (17%) to $3.16 on Tuesday after it granted Basilea Pharmaceutica Ltd. (SIX:BSLN...
...and Taiwan to derazantinib. Basilea was off CHF1.60 to CHF66.40 on Tuesday. Jennie Walters Derazantinib (ARQ 087) ArQule Inc. Basilea Pharmaceutica Ltd. Fibroblast...
BioCentury | Mar 7, 2018
Company News

Management tracks: Alliance, Anika

...gastroenterologist and professor of medicine at Mayo Clinic (Rochester, Minn.). Infectious disease and cancer company Basilea Pharmaceutica Ltd....
BioCentury | Feb 26, 2018
Company News

Management tracks: Vertex, Basilea

...remain a senior adviser to the company through early 2019. Infectious disease and cancer company Basilea Pharmaceutica Ltd....
BioCentury | Nov 2, 2017
Company News

Management tracks: Melinta, Lundbeck

...officer of Lundbeck, effective Oct. 31 (see BioCentury Extra, Sept. 11) . Infectious disease company Basilea Pharmaceutica Ltd....
Items per page:
1 - 10 of 343
BioCentury | May 30, 2020
Management Tracks

Schneyer named Acadia CBO; plus Hansa, MaaT, iOnctura, First Light, Oligomerix, Galecto and Hyloris

...Kaufhold will become CMO, a newly created position. Before joining the autoimmune company, he served Basilea Pharmaceutica Ltd....
BioCentury | Jan 24, 2020
Preclinical News

Jan. 23 Preclinical Quick Takes: Metastasis-associated cancer-associated fibroblast populations; plus NIH-TeneoBio and Basilea

...a presentation at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO), Basilea Pharmaceutica Ltd....
...growth factor β BioCentury Staff TeneoBio Inc. Institut Curie Institut National de la Sante et de la Recherche Medicale (INSERM) Basilea Pharmaceutica Ltd. National...
BioCentury | May 2, 2019
Company News

Forge, Basilea to develop antibiotics against unexploited targets

...plus tiered royalties. Basilea Pharmaceutica International Ltd. is a subsidiary of Basilea Pharmaceutica Ltd. (SIX:BSLN). Shannon Lehnbeuter, Staff Writer Basilea Pharmaceutica Ltd. Forge...
BioCentury | Feb 12, 2019
Company News

Management tracks: Sanofi, Alexion, bluebird

...succeeds Eva-Maria Joed, who will become VP of finance and administration. Spota was CFO at Basilea Pharmaceutica AG...
BioCentury | Jan 18, 2019
Clinical News

Derazantinib leads to 21% ORR in Phase II intrahepatic cholangiocarcinoma cohort

...also plans to start in mid-2019 a Phase II trial in other FGFR-driven solid tumors. Basilea Pharmaceutica Ltd....
...ORR); disease control rate (DCR) Status: Interim Phase II data Milestone: NA Hongjiang Li Derazantinib (ARQ 087) ArQule Inc. Basilea Pharmaceutica Ltd. Fibroblast...
BioCentury | Apr 20, 2018
Company News

Basilea gains rights to ArQule's derazantinib

...ArQule Inc. (NASDAQ:ARQL) granted Basilea Pharmaceutica Ltd. (SIX:BSLN) exclusive rights to develop and commercialize derazantinib (ARQ 087) outside...
...derazantinib. ArQule Inc. (NASDAQ:ARQL), Burlington, Mass. Basilea Pharmaceutica Ltd. (SIX:BSLN), Basel, Switzerland Business: Cancer Jennie Walters Derazantinib (ARQ 087) ArQule Inc. Basilea Pharmaceutica Ltd. The...
BioCentury | Apr 17, 2018
Company News

Basilea gains rights to ArQule's derazantinib

...ArQule Inc. (NASDAQ:ARQL) shares rose $0.46 (17%) to $3.16 on Tuesday after it granted Basilea Pharmaceutica Ltd. (SIX:BSLN...
...and Taiwan to derazantinib. Basilea was off CHF1.60 to CHF66.40 on Tuesday. Jennie Walters Derazantinib (ARQ 087) ArQule Inc. Basilea Pharmaceutica Ltd. Fibroblast...
BioCentury | Mar 7, 2018
Company News

Management tracks: Alliance, Anika

...gastroenterologist and professor of medicine at Mayo Clinic (Rochester, Minn.). Infectious disease and cancer company Basilea Pharmaceutica Ltd....
BioCentury | Feb 26, 2018
Company News

Management tracks: Vertex, Basilea

...remain a senior adviser to the company through early 2019. Infectious disease and cancer company Basilea Pharmaceutica Ltd....
BioCentury | Nov 2, 2017
Company News

Management tracks: Melinta, Lundbeck

...officer of Lundbeck, effective Oct. 31 (see BioCentury Extra, Sept. 11) . Infectious disease company Basilea Pharmaceutica Ltd....
Items per page:
1 - 10 of 343